



# Biotech Daily

Thursday August 7, 2025

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH EVEN: 4D MEDICAL UP 20%; CLARITY DOWN 6%**
- \* **NEUREN H1 DAYBUE SALES UP 13% TO \$278m; ROYALTY UP 15% TO \$28m**
- \* **IDT EXPECTS REVENUE UP 41% TO \$19.9m; LOSS UP 39% TO \$7.5m**
- \* **ATOMO \$630k LUMOS PASCAL FEBRIDX SUPPLY DEAL**
- \* **TRYPTAMINE, SWINBURNE TRP-8803 PSILOCIN SUPPLY PERMIT**
- \* **PHILLIP ASSET, BIOSCIENCE MANAGERS TAKE 18.5% OF ADHERIUM**
- \* **AVITA APPOINTS DR MICHAEL TARNOFF DIRECTOR;  
CARY VANCE REPLACES 10-YEAR AVITA CHAIR LOU PANACCIO**
- \* **IDT LOSES CEO PAUL MCDONALD; NEW CEO WANTED**
- \* **TAITRA \$138k TAIWAN PROJECT AWARDS - 1 WEEK TO GO**

## MARKET REPORT

The Australian stock market fell 0.14 percent on Thursday August 7, 2025, with the ASX200 down 12.3 points to 8,831.4 points.

Seventeen of the Biotech Daily Top 40 companies were up, 17 fell and six traded unchanged. The four Big Caps were mixed.

4D Medical was the best for the second day in a row, up eight cents or 20.25 percent to 47.5 cents, with 6.6 million shares traded.

Universal Biosensors climbed 9.5 percent; Immutep and Starpharma were up more than seven percent; Medical Developments was up 6.6 percent; Amplia and Resonance were up more than five percent; Actinogen, Alcidion, Curvebeam, Dimerix and Proteomics improved more than four percent; Neuren and Orthocell were up more than three percent; Avita, Emvision and SDI rose more than two percent; with Cochlear and Pro Medicus up by less than one percent.

Clarity led the falls, down 28 cents or six percent to \$4.38, with 4.9 million shares traded. Botanix, Nova Eye and Optiscan lost more than three percent; Cynata, Mesoblast, Resmed and Telix shed more than two percent; CSL, Genetic Signatures, Imugene, Medadvisor, Nanosonics, Polynovo and Syntara were down more than one percent; with Aroa, Clinuvel, Cyclopharm and EBR down by less than one percent.

## NEUREN PHARMACEUTICALS

Neuren says Acadia reported net sales of Daybue for the six months to June 30, 2025 up 12.6 percent to \$US180.7 million (\$A277.7 million), with royalties of \$A28.2 million.

Neuren said sales of trofenitide for Rett syndrome, marketed by North America partner Acadia Pharmaceuticals as Daybue, for the three months to June 30, 2025 were up 14 percent to \$US96.1 million, with royalties of \$A14.7 million.

In 2023, the company said its North American partner, the San Diego-based Acadia had US Food and Drug Administration approval for Daybue, or trofenitide, for Rett syndrome for people over the age of two years (BD: Mar 13, 2023).

Last year, Neuren said Acadia reported net sales of Daybue for the six months to June 30, 2024 of \$US160.5 million, earning it royalties of \$A24.6 million (BD: Aug 7, 2024).

In May, the company said US sales of Daybue for the three months to March 31, 2025 were \$US84.6 million, with royalties of \$A13.5 million (BD: May 8, 2025).

Today, Neuren said the increase in sales was “primarily due to the growth in unit sales shipped to more unique patients” and that in the three months a record number of US patients received shipments for the third consecutive three-month period.

The company said the number of patients receiving Daybue continued to increase and reached a record high of 987 patients, up from 954 patients in the three months to March 31, 2025 and 920 patients in the three months to December 31, 2024.

Neuren said the persistency rate of patients remained “steady above 50 percent after 12 months of treatment [and] 70 percent of active patients have now been on therapy for 12 months or longer, up from 65 percent”.

The company said Acadia had “reiterated its full-year 2025 guidance for Daybue US net sales of \$US380 million to \$US405 million” and if guidance was met it expected between \$A62 million and \$A67 million in US sales royalties.

In February, Neuren said Acadia Daybue US sales for the year to December 31, 2024 were up 96.6 percent to \$US348.4 million (BD: Feb 27, 2025).

Neuren was up 54 cents or 3.2 percent to \$17.55 with 1.1 million shares traded.

## IDT AUSTRALIA

IDT says it expects unaudited revenue for the year to June 30, 2025 to be up 46.45 percent to \$19.9 million, with net loss expected to increase 38.9 percent to \$7.5 million.

Last year, IDT said revenue from sales of its specialty oral products including marijuana and psychedelics, active pharmaceutical ingredients and advanced therapies for the year to June 30, 2024 was up 93.2 percent to \$13,588,000, with net loss after tax down 36.3 percent to \$5,413,000 (BD: Aug 26, 2024).

Today, the company said the revenue increase was partly due to improved disbursement revenue of \$4,800,000, compared with \$900,000 in the prior year, which included raw material costs and equipment, which it charged customers for with a modest margin.

IDT said earnings “were negatively impacted by the recognition of bad debts of circa \$1.2 million relating to two customers defaulting on payments in 2024-’25”.

The company said the debts were one-off items and it was “reviewing all procedures in place to improve the review and due diligence undertaken on new clients to ensure the quality of our contracted clients is increased and minimize events of this nature”.

IDT said demand for services was “strong, and the company continues its commitment to the transformation program launched three years ago to restore profitability”.

The company said “under new leadership, IDT will conduct a comprehensive review of operational and business activities to accelerate progress toward this goal” (see below).

IDT fell 1.6 cents or 17.8 percent to 7.4 cents with 1.8 million shares traded.

### ATOMO DIAGNOSTICS

Atomo says it has a \$US410,000 (\$A630,000) order for its Pascal cassettes from Lumos “to support scale-up of Febridx demand in the US”.

Last month, Lumos said it had an up-to \$US317 million, six-year distribution and supply deal with Hong Kong’s Phase Scientific International Ltd for its Febridx test for bacterial and viral respiratory infections, subject to a US Food and Drug Administration clinical laboratory improvement amendments (CLIA)-waiver (BD: Jul 17, 2025).

Today, Atomo said the Febridx test used its Pascal test cassette to “deliver improved usability and reliability in point of care settings ... [and it was] “the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos for its Febridx product”.

Atomo said it expected “a significant increase in demand for its Pascal cassette in the US”.

Atomo managing-director John Kelly said the company was “very pleased to see demand for Pascal locked into a sizable long-term contract in the US market and stand ready to work with Lumos to support supply of Pascal into Lumos’s supply chain and scale up of operations to meet demand for Febridx.”

Atomo was unchanged at two cents with 9.1 million shares traded.

### TRYPTAMINE THERAPEUTICS (FORMERLY EXOPHARM)

Tryptamine says Melbourne’s Swinburne University of Technology has a permit to receive supply of its TRP-8803 psilocin to use in a trial of the drug for binge eating disorder.

Earlier this year, Tryptamine said it would conduct a 12-patient, open-label trial of intravenous TRP-8803 for binge eating disorder with Swinburne (BD: Apr 10, 2025).

Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in ‘magic mushrooms’ (BD: Jul 1, 2024).

Today, Tryptamine said batches of TRP-8803 were “expected to be delivered in the near term, ensuring ample supply for the trial”.

The company said patient screening was progressing well and “initial enrolments will begin with ... baseline data collection, prior to administration of first dosing”.

Tryptamine chief executive officer Jason Carroll said the company continued “to make very strong progress in relation to its trial with Swinburne and the receipt of this permit marks another milestone in our journey to deliver a potential treatment for [binge eating disorder], which is a far reaching and debilitating condition”.

“Our focus will now shift to supplying Swinburne with TRP-8803 for use in the trial, as well as assisting with patient enrolment,” Mr Carroll said.

“Given the level of enquiries to date and progress with initial patient screening, we remain on track for first enrolment this month and first dosing this quarter,” Mr Carroll said.

Tryptamine was up 0.1 cents or 3.1 percent to 3.3 cents with 2.3 million shares traded.

### ADHERIUM

Phillip Asset Management Ltd says it has increased its substantial shareholding in Adherium from 287,562,238 shares (16.00%) to 343,770,320 shares (18.45%).

The Melbourne-based Phillip Asset said as trustee for Bioscience Managers it bought 56,208,082 shares in a placement on August 4 for \$281,040, or 0.5 cents a share.

On Monday, Adherium said it had “firm commitments” to raise \$350,000 at 0.5 cents a share in a placement, with one option for every share issued (BD: Aug 4, 2025).

Adherium was untraded at 0.4 cents.

### AVITA MEDICAL

Avita says it has appointed Dr Michael Tarnoff as a director, effective from August 6, with director Cary Vance to replace chair Lou Panaccio, effective from August 7, 2025.

Avita said Dr Tarnoff had been chief executive officer at Tufts Medical Center, chief medical officer at Medtronic and chief medical officer of surgical devices at Covidien, medical director at GI Dynamics and chief medical consultant at Tyco Healthcare.

The company said Dr Tarnoff held a Bachelor of Arts from St Louis, Missouri's Washington University and a Doctor of Medicine from the University of Medicine and Dentistry of New Jersey.

Avita said Mr Panaccio had stepped down from the role of chair and that Mr Vance had been a director of the company since April 1, 2023 (BD: Mar 17, 2023).

Avita chief executive officer Jim Corbett thanked Mr Panaccio of his more than 10 years of service as board chair.

"On behalf of the entire company and the board, I want to express our deepest gratitude to Lou," Mr Corbett said. "His leadership as our board chair has reflected his enduring dedication to our mission and the growth of our company."

Avita was up 3.5 cents or 2.1 percent to \$1.725.

### IDT AUSTRALIA

IDT says chief executive officer Paul McDonald has resigned, with immediate effect, and chair Mark Simari will assume the role of executive chair.

IDT said acknowledged Mr McDonald's "contribution since joining the company in 2021 and wishes him well for the future" (BD: Mar 2, 2023).

The company said it would "commence a search for a new [chief executive officer] over coming months to complement our team and strategy".

### TAIWAN EXTERNAL TRADE DEVELOPMENT COUNCIL

The Taiwan External Trade and Development Council (TAITRA) says submission for its 'Go Healthy with Taiwan' \$US90,000 (\$A138,000) project awards close in one week.

Earlier this year, a media release from the Taiwan Ministry of Economic Affairs'

International Trade Administration said it had commissioned TAITRA to award \$US90,000 to three medical companies and/or researchers with proposals using "Taiwan's high-quality products and holistic solutions" (BD: Jun 16, 2025).

At that time, the Council said that the funds included cash and support as part of its 'Go Health with Taiwan' program for biotechnology companies, entrepreneurs, innovators or researchers with health-related initiatives or ideas that would benefit from the inclusion of Taiwanese products or technology.

TAITRA said six finalists would be flown to Taiwan to present their proposals, with three winners to receive a prize of \$US30,000, each.

For more information go to: <https://gohealthy.taiwanexcellence.org/about.html>.